The clinical ramifications were equally profound, prompting use of pulsatile GnRH therapies to treat hypothalamic hypo‐gonadotropism, and non‐pulsatile GnRH agonist treatments to suppress gonadotropin secretions in precocious puberty or prostate cancer therapies. This evidence concerns the gene GNRH1 and prostate carcinoma.